首站-论文投稿智能助手
典型文献
A targeted covalent inhibitor of p97 with proteome-wide selectivity
文献摘要:
A resurging interest in targeted covalent inhibitors(TCIs)focus on compounds capable of irreversibly reacting with nucleophilic amino acids in a druggable target.p97 is an emerging protein target for cancer therapy,viral infections and neurodegenerative diseases.Extensive efforts were devoted to the development of p97 inhibitors.The most promising inhibitor of p97 was in phase 1 clinical trials,but failed due to the off-target-induced toxicity,suggesting the selective inhibitors of p97 are highly needed.We report herein a new type of TCIs(i.e.,FL-18)that showed proteome-wide selectivity towards p97.Equipped with a Michael acceptor and a basic imidazole,FL-18 showed potent inhibition towards U87MG tumor cells,and in proteome-wide profiling,selectively modified endogenous p97 as confirmed by in situ fluorescence scanning,label-free quantitative proteomics and functional validations.FL-18 selectively modified cysteine residues located within the D2 ATP site of p97.This covalent labeling of cysteine residue in p97 was verified by LC-MS/MS-based site-mapping and site-directed mutagenesis.Further structure-activity relationship(SAR)studies with FL-18 analogs were established.Collectively,FL-18 is the first known small-molecule TCI capable of covalent engagement of p97 with proteome-wide selectivity,thus providing a promising scaffold for cancer therapy.
文献关键词:
作者姓名:
Zi Ye;Ke Wang;Lianguo Chen;Xiaofeng Jin;Hao Chen;Guanghui Tang;Shao Q.Yao;Zhiqiang Feng;Chong-Jing Zhang
作者机构:
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Drugability Evaluation,Institute of Materia Medica Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100050,China;Department of Chemistry,National University of Singapore,Singapore 117543,Singapore
引用格式:
[1]Zi Ye;Ke Wang;Lianguo Chen;Xiaofeng Jin;Hao Chen;Guanghui Tang;Shao Q.Yao;Zhiqiang Feng;Chong-Jing Zhang-.A targeted covalent inhibitor of p97 with proteome-wide selectivity)[J].药学学报(英文版),2022(02):982-989
A类:
p97,TCIs
B类:
targeted,covalent,proteome,wide,selectivity,resurging,interest,inhibitors,focus,compounds,capable,irreversibly,reacting,nucleophilic,amino,acids,druggable,emerging,protein,cancer,therapy,viral,infections,neurodegenerative,diseases,Extensive,efforts,were,devoted,development,most,promising,was,phase,clinical,trials,but,failed,off,induced,toxicity,suggesting,are,highly,needed,We,report,herein,new,type,FL,that,showed,towards,Equipped,Michael,acceptor,basic,imidazole,potent,inhibition,U87MG,tumor,cells,profiling,selectively,modified,endogenous,confirmed,by,situ,fluorescence,scanning,free,quantitative,proteomics,functional,validations,cysteine,residues,located,within,D2,ATP,site,This,labeling,verified,LC,mapping,directed,mutagenesis,Further,structure,activity,relationship,SAR,studies,analogs,established,Collectively,first,known,small,molecule,engagement,thus,providing,scaffold
AB值:
0.564491
相似文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766
Zean Li;Jun Huang;Tao Du;Yiming Lai;Kaiwen Li;Man-Li Luo;Dingjun Zhu;Jun Wu;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510220,China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Medical Research Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;School of Biomedical Engineering,Sun Yat-sen University,Shenzhen 518107,China;Department of Obstetrics and Gynecology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou;Xiao Li;Li-ping Liao;Jie Han;Jing Huang;Jia-cheng Li;Hong-ru Tao;Shi-jie Fan;Zhi-feng Chen;Qi Li;Shi-jie Chen;Hong Ding;Ya-xi Yang;Bing Zhou;Hua-liang Jiang;Kai-xian Chen;Yuan-yuan Zhang;Chuan-xin Huang;Cheng Luo-Drug Discovery and Design Center,The Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China;Department of Medicinal Chemistry,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shanghai Institute of Immunology and Department of Immunology and Microbiology,Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,Faculty of Basic Medicine,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase
Wen Li;Li-ping Liao;Ning Song;Yan-jun Liu;Yi-luan Ding;Yuan-yuan Zhang;Xiao-ru Zhou;Zhong-ya Sun;Sen-hao Xiao;Hong-bo Wang;Jing Lu;Nai-xia Zhang;Hua-liang Jiang;Kai-xian Chen;Chuan-peng Liu;Jie Zheng;Ke-hao Zhao;Cheng Luo-School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai 264005,China;Drug Discovery and Design Center,the Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Center of Immunological Diseases,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Gastroenterology,Xinhua Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 201210,China;Department of Analytical Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;School of Life Science and Technology,Shanghai Tech University,Shanghai 201210,China;School of Life Science and Technology,Harbin Institute of Technology,Harbin 200092,China;Department of Pharmacology,College of Pharmacy,Fujian Medical University,Fuzhou 350108,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。